Gilead gains access to tumor myeloid targets via Pionyr partnership
Each of Gilead’s five cancer deals this year have given it a line to a new immuno-oncology approach
Gilead’s tie-up with Pionyr marks the big biotech’s fifth cancer deal this year and gives it access to mAbs against immunosuppressive tumor myeloid cells.
In an agreement announced Tuesday, Gilead Sciences Inc. (NASDAQ:GILD) will pay $275 million up front to acquire 49.9% of Pionyr Immunotherapeutics Inc. and an exclusive option to buy the remainder of the company.
Pionyr CBO Alicia Levey told
